Durham drug developer Scynexis posted a $1.2 million loss this week in the company’s first earnings release since its public stock offering last month.
The 90-employee company’s first-quarter loss compares to a loss of $2.1 million in the first quarter a year ago.
Scynexis, which spun out of Aventis in 2000, does not have a drug on the market. It’s developing SCY-078, a treatment for serious and life-threatening fungal infections.
The experimental drug stemmed from a collaboration between Scynexis and pharmaceutical giant Merck. Last year Merck returned the development and commercialization rights to Scynexis.
The company posted first quarter revenue of $1.8 million, same as a year earlier. The money was generated from R&D contract work for other companies.
Scynexis’s focus for the rest of 2014 will be developing an oral and intravenous formulation of SCY-078.
Its shares were at $9.77 in midday trading, up 13 cents. The company’s shares began trading at $10 last month.